Comparing FIB-4 and MAF-5 for Advanced Fibrosis Screening in Primary Care

Complete the form to access the poster and explore the preliminary GRIPonMASH findings.

Name(Required)

As the prevalence of MASLD and MASH continues to rise, identifying patients with advanced fibrosis earlier and more efficiently has become increasingly important for both clinical care and therapeutic development.

This poster, presented at EASL 2026, shares preliminary findings from the GRIPonMASH consortium comparing two non-invasive first-line screening tools, FIB-4 and MAF-5, in 2,038 at-risk individuals recruited through primary care and population-based approaches across 10 European countries.

Using liver stiffness measurement (VCTE) as the reference standard, researchers evaluated each tool’s ability to rule out advanced fibrosis and assessed performance across key patient populations, including individuals with type 2 diabetes, obesity, and hypertension.

The findings provide valuable insights into real-world patient identification strategies and highlight the opportunities and trade-offs associated with different approaches to fibrosis screening. For organizations developing therapies for MASH and related metabolic diseases, these results help inform scalable approaches to identifying patients at risk of advanced liver disease.

Key Insights

  • Comparison of FIB-4 and MAF-5 as first-line fibrosis screening tools
  • Data from 2,038 participants recruited across 10 European countries
  • Evaluation of negative predictive value, sensitivity, and referral rates for second-line testing
  • Subgroup analyses by sex and cardiometabolic comorbidities
  • Insights into scalable patient identification strategies for advanced fibrosis and MASH research
  • Preliminary evidence supporting optimization of fibrosis screening pathways in primary care settings

P95 Julius Clinical Authors

This research includes contributions from Vivian de Jong, Project Manager, Caterina Buranelli, Real-World Evidence Statistician, Rick Grobbee, Scientific Officer, and Manuel Castro Cabezas, Scientific Officer, all of P95 Julius Clinical, as part of the GRIPonMASH consortium.